Viracta Therapeutics: Positive Phase 2 NAVAL-1 Trial Data, Regulatory Progress, and Future Clinical Plans. Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company, recently shared positive data from the Phase 2 NAVAL-1 trial, which focuses on relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL). This article aims to provide a comprehensive overvi...
$Viracta Therapeutics (VIRX.US)$Viracta Therapeutics Announces Positive Data From the Phase 2 Naval-1 Trial, Regulatory Progress, and Updated Nana-Val Clinical Development Plan
Viracta Therapeutics股票討論
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company, recently shared positive data from the Phase 2 NAVAL-1 trial, which focuses on relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL). This article aims to provide a comprehensive overvi...
$Avalon GloboCare (ALBT.US)$
苯甲· 7 分鐘前
暫無評論